Insmed Incorporated (NASDAQ:INSM) Receives $81.40 Consensus Target Price from Brokerages

Insmed Incorporated (NASDAQ:INSM) has been given an average rating of “Buy” by the sixteen brokerages that are presently covering the company, MarketBeat reports. Sixteen research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $81.53.

A number of research firms have weighed in on INSM. JPMorgan Chase & Co. boosted their target price on shares of Insmed from $72.00 to $74.00 and gave the stock an “overweight” rating in a report on Thursday. Truist Financial lowered their target price on Insmed from $88.00 to $85.00 and set a “buy” rating for the company in a research report on Monday, August 12th. UBS Group upped their price target on Insmed from $78.00 to $84.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Mizuho raised their price objective on Insmed from $36.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, June 7th. Finally, The Goldman Sachs Group upped their target price on Insmed from $74.00 to $102.00 and gave the company a “buy” rating in a report on Wednesday, July 10th.

Insiders Place Their Bets

In other news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the transaction, the insider now owns 100,100 shares of the company’s stock, valued at approximately $7,157,150. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the sale, the insider now owns 106,134 shares in the company, valued at approximately $7,951,559.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the transaction, the insider now owns 100,100 shares in the company, valued at approximately $7,157,150. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 78,882 shares of company stock worth $5,765,446. 4.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Insmed

Hedge funds and other institutional investors have recently made changes to their positions in the business. EntryPoint Capital LLC acquired a new position in Insmed during the 1st quarter valued at about $33,000. Fidelis Capital Partners LLC bought a new stake in Insmed during the first quarter worth $34,000. First Horizon Advisors Inc. raised its position in Insmed by 83.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 287 shares during the last quarter. Headlands Technologies LLC bought a new position in Insmed during the 1st quarter valued at $59,000. Finally, CWM LLC boosted its holdings in Insmed by 11.0% during the 2nd quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 155 shares during the last quarter.

Insmed Stock Down 2.2 %

Shares of NASDAQ:INSM opened at $71.40 on Friday. Insmed has a 52-week low of $21.92 and a 52-week high of $80.53. The company has a market capitalization of $10.61 billion, a PE ratio of -13.65 and a beta of 1.11. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. The company has a fifty day moving average of $74.07 and a 200-day moving average of $54.70.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.72). The business had revenue of $90.34 million during the quarter, compared to analyst estimates of $87.95 million. During the same period in the previous year, the firm posted ($1.78) earnings per share. The firm’s quarterly revenue was up 17.0% on a year-over-year basis. On average, equities analysts predict that Insmed will post -5.42 EPS for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.